Long-term Isturisa Lessens Cushing’s Physical Features, Trial Data Show
Nearly 1.5 years of treatment with Isturisa (osilodrostat) rapidly and sustainably eased — and in many cases completely eliminated — disease-associated physical features in people with Cushing’s disease, according to data from the Phase 3 LINC 3 trial. Improvements were noted from early on, consistent with the…